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Abstract 
The ubiquitous second messenger 
cAMP mediates signal transduction 
processes in the malarial parasite that 
regulate host erythrocyte invasion and the 
proliferation of merozoites.  In 
Plasmodium falciparum the central 
receptor for cAMP is the single regulatory 
subunit (R) of Protein kinase A (PKA).  To 
aid the development of compounds that 
can selectively dysregulate parasite PKA 
signalling we solved the structure of the 
PKA regulatory subunit in complex with 
cAMP and a related analog that displays 
antimalarial activity: Sp-2Cl-cAMPS.  Prior 
to signalling, PKA-R holds the kinaseǯs 
catalytic subunit (C) in an inactive state by 
exerting an allosteric inhibitory affect.  
When two cAMP molecules bind to PKA-R 
they stabilise a structural conformation 
that facilitates its dissociation, freeing 
PKA-C to phosphorylate down-stream 
substrates such as Apical Membrane 
Antigen 1.  While PKA activity was known 
to be necessary for erythrocytic 
proliferation we show that uncontrolled 
induction of PKA activity using membrane 
permeable agonists is equally disruptive 
to growth.   
 
Introduction 
Despite significant inroads in 
mitigating their toll on human health, 
Plasmodium parasites, the causative 
agents of malaria, remain deadly human 
pathogens (1) (2).  Their complex parasitic 
life cycle alternates between mosquito and 
vertebrate hosts, however it is the asexual 
intraerythrocytic stage with which disease 
is associated. To ensure timely and 
successful transmission and propagation, 
the parasite must constantly monitor its 
surroundings in order to coordinate its 
development.  At the molecular level signal 
transduction pathways orthologous to 
those found in other eukaryotes are 
responsible for dynamic post-
transcriptional phosphorylation reactions 
that control key developmental proteins 
(3). The phylum Apicomplexa to which 
Plasmodium belongs, is evolutionary 
distant to most commonly studied 
organisms (4) and significant phylogenetic 
diversity thus separates the Plasmodium 
kinome from other studied systems.  This 
diversity can be exploited though if 
inhibitory compounds can be developed 
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enzymes while leaving orthologous human 
variants unaffected (5). 
 
As in other eukaryotic species 
Plasmodium developmental pathways 
utilise the diffusible second messenger ͵ǯ-ͷǯ-cyclic adenosine monophosphate 
(cAMP), the main effector for which is the 
cAMP-dependent kinase: protein kinase A 
(6).  cAMP-dependent signalling is 
generally activated when ligands bind to 
membrane bound receptors that go on to 
activate intracellular adenylate cyclases, 
yielding a localised rise in the cAMP 
concentration and hence activation of PKA.  
P. falciparum PKA activity is instrumental 
to a number of molecular mechanisms, 
including merozoite egress, motility and 
red blood cell invasion (7,8), schizogony 
(7) and the progression from schizonts to 
invasive merozoites (9).  Specifically, 
during merozoite invasion PfPKA has been 
implicated in regulating microneme 
secretion of erythrocyte host-recognition 
receptors (10), and once inside the host 
cell PKA signalling pathways influence 
parasite growth and differentiation (11) 
possibly by initiating the formation of new 
permeation pathways (12). Following 
differentiation into gametocytes cAMP-
dependent kinase activity has also been 
found to regulate the host cell membranes 
stiffness in order to prevent splenic 
clearance (13).  
 
PKA orthologues are ubiquitous 
amongst eukaryotes and are composed of 
a catalytic kinase subunit (PKA-C) in 
association with a regulatory subunit 
(PKA-R) containing two cAMP-binding 
sites.  Compounds that specifically inhibit 
the Plasmodium PKA-C kinase domain are 
known to block parasite development 
(14).  Less is known about the action of the 
PfPKA-R subunit and whether this can also 
be therapeutically targeted. Mammalian 
PKA has been extensively studied and 
serves as a useful frame of reference from 
which to understand the distinct P. 
falciparum PKA system (15).  In mammals, 
the regulatory PKA-R subunit is a highly 
dynamic molecular switch (16) (17) that 
serves as a competitive inhibitor of the 
catalytic subunit, holding it inactive in the 
absence of cAMP but rapidly releasing its 
inhibitory check as the cAMP 
concentration rises.  Mammals have four 
R-subunit isoforms within their PKA 
systems, which are split into related type I 
and type II pairs (RIȽ and IȾ, IIȽ and IIȾ 
respectively) (18).  Each of these isoforms 
are functionally distinct and influence 
their respective holoenzymes cellular 
localization, sensitivity to activation and 
regulatory feedback mechanisms (19).  In 
contrast, the unicellular Plasmodium 
parasites contain a single PfPKA-R subunit 
whose features appear to be a hybrid of 
the mammalian subtypes (15).  Primary 
structure analysis indicates that 
Plasmodium PKA-R has a its own loosely 
structured N-terminal sequence but, as in 
mammalian R subunits, the C-terminus 
contains two consecutive cyclic 
nucleotide-binding domains (CBDs).  
These CBDs share ~35% sequence 
identity with their mammalian 
equivalents, and ~54% identity with non-
plasmodium Apicomplexans.  
 
The CBDs themselves are an 
ancient signalling module often found in 
enzymes regulated by cAMP or cGMP (20), 
their fold consists of a conserved 8-
stranded Ⱦ-barrel along with three or more accessory Ƚ-helices.  Cyclic 
nucleotides typically insert phosphate-first into the barrelǯs core and in doing so 
induce structural rearrangements of the Ƚ-
helices to induce the second messenger 
response.  In human PKA holoenzymes, the 
catalytic kinase subunit (C) is held inactive 
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through its association with the apo 
dumbbell shaped PKA-R subunits, a shape 
derived from the two CBDs lying on either 
side of a rigid connecting helix (21).  This 
dumbbell shape exposes two inhibitory 
regions: a pseudosubstrate sequence N-
terminal to CBD1 that locks into the kinase domainǯs active site; and the helix between 
the two CBDs that binds to the large lobe 
of the kinase domain and prevents 
catalytically necessary Ǯbreathingǯ 
motions.  These mutual inhibitory effects 
are lost when cyclic nucleotide binding 
causes the regulatory domainǯs dumbbell 
shape to collapse into a more compact 
form that masks the kinase domain-
interacting regions facilitating subunit 
dissociation (17).  The catalytic domain is 
thus freed from its allosteric restraint 
allowing it to transmit and amplify the 
cAMP signal to multiple downstream 
targets via its kinase activity.  We sought to 
assess to what extent this molecular 
activation mechanism is conserved in 
PfPKA-R.  Furthermore we examine the 
effects on parasite growth of membrane 
permeable compounds that cause PKA 
dysregulation through premature 
activation of the holoenzyme. 
 
Results 
Expression of the Plasmodium 
falciparum PKA regulatory subunit. 
The P. falciparum 3D7 genome contains a 
single 441 amino acid PfPKA-R subunit 
(PlasmoDB# PF3D7_1223100) known to 
associate with a cAMP-inducible kinase 
activity (12).  The PfPKA-R sequence 
encompasses two predicted cyclic-
nucleotide binding domains: CBD1 
(residues 166-294) and CBD2 (residues 
310-441) (Fig. 1).  We cloned, expressed 
and purified four PfPKA-R constructs 
spanning either one or both CBD (residues 
2-441, 69-441, 141-441 and 297-441).  
The constructs PfPKA-R.141.441 and 
PfPKA-R.297.441 expressed with 5-10 
mg/L yields and were thus favoured for 
further study (Fig. 1).   
 
Following purification of the 
PfPKA-R constructs UV-visible light 
absorbance spectra indicated the presence 
of a 260nm absorbance peak presumed to 
be bound nucleotide scavenged from the E. 
coli lysate.  To liberate these PfPKA-R-
bound nucleotides, we performed a 
standard soluble expression protocol but 
retained PfPKA-R.141.441 on the 
immobilised metal affinity column, 
washed with progressively higher 
concentrations of urea-containing buffers, 
and slowly returned to a standard buffer 
prior to protein elution and further 
purification. Absorbance measurements 
indicated that ~50 column volumes of 8M 
urea were required to liberate all bound 
nucleotide.  This refolded apo-PfPKA-
R.141.441 sample represents a 
conformation of PfPKA-R with two empty 
CBD binding sites primed for re-
association with the PKA-C (22).  This on 
column refolding reduced total protein 
yield (~1mg/L) from that of a standard 
soluble purification (~5mg/L).  We append the prefix ǲapo-“ to distinguish 
between PfPKA-R purifications that 
required nucleotide dissociation (kinase 
and affinity assays and drug-bound 
structures). 
 
Recombinant PfPKA-R is functionally 
active. 
To verify that the recombinant apo-PfPKA-
R.141.441 was active, we aimed to 
investigate if it could block PKA-C activity 
and thus inhibit PfPKA-driven 
phosphorylation. Unfortunately, we were 
unable to bacterially express soluble 
recombinant PfPKA-C and instead utilised 
late-stage P. falciparum schizont lysates as 
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our kinase source.  The cytoplasmic tail of 
Apical Membrane Antigen 1 (AMA1), 
which is a highly validated target of PfPKA 
(23) (8) (24) was used as our kinase 
substrate. The AMA1-tail is 
phosphorylated by PfPKA at amino acid 
S610 and this event is required for 
merozoite invasion of erythrocytes by P. 
falciparum (8).  For our assays, the 56 
amino-acid (aa) AMA1-tail was expressed 
as a fusion with glutathione S transferase 
(GST) and immobilised in the wells of an 
ELISA microplate (Fig. 2A).  Schizont lysate 
was added to each well with varying 
concentrations of cAMP to stimulate 
PfPKA phosphorylation, and/or 
recombinant PfPKA-R to inhibit 
phosphorylation. Following the reaction, 
phosphorylation of S610 was detected 
with a highly specific antibody raised to a 
synthetic S610p phosphopeptide (Fig. 2A) 
(23).  In the absence of supplementary 
apo-PfPKA-R or cAMP, phosphorylation of 
AMA1 was quite low, indicating minimal 
levels of PfPKA-C activity in the parasite 
lysates (Fig. 2B). This activity was 
however strongly boosted by addition of 
supplementary cAMP. Furthermore, 
addition of our apo-PfPKA-R fragment 
strongly suppressed AMA1 
phosphorylation in a concentration-
dependent manner presumably because it 
allosterically inhibited native PfPKA-C 
(Fig. 2B).  Importantly, this inhibitory 
activity could be reversed in a 
concentration-dependent fashion by 
increasing amounts of supplementary 
cAMP (Fig. 2B).   
 
 To ensure that this inhibitory effect 
was specifically due to the action of the 
recombinant protein and not a non-
specific contaminant, we heated the 
recombinant protein and repeated the 
assay.  The heat-denatured protein was 
poorly efficient at inhibiting AMA1 
phosphorylation when compared with the 
untreated protein validating that 
inhibition was due to recombinant apo-
PfPKA-R (Fig. 2B).  Our recombinantly 
produced regulatory subunit thus associates with the parasiteǯs catalytic 
subunit influencing its activity.  
 
Structure of the PfPKA-R subunit. 
Broad screens identified conditions 
facilitating protein crystal growth for the 
PfPKA-R.141.441 and 297.441 constructs 
in complex with cAMP, with X-ray 
diffraction data then obtained to 2.0 Å and 
1.1 Å resolution, respectively.  Initial 
electron density maps were calculated 
using phases obtained via molecular 
replacement (see materials and methods 
for details).   
 
Our final model of PfPKA-
R.141.441 has clear electron density for all 
structural elements of the two CBD 
modules (Fig. 3A,B).  These are accorded 
standard nomenclature for the fold, which 
comprises eight Ⱦ-strands ȋȾͳ-8); three major helices ȋȽA, ȽB and ȽCȌ; a short 
helical turn overlaying the phosphate moiety ȋȽPȌ and an N-terminal helical element ȋȽNȌ.  Figure 3C delineates the 
residues within each structural element, 
with those from CBD2 referenced using a 
suffixing quotation mark (e.g. ȽA`Ȍ.  The 
asymmetric unit of the PfPKA-R.141.441 
crystals contained two protomers related 
by non-crystallographic symmetry whose 
structural differences are limited to 
different side chain conformations within 
surface residues.  During the refinement of 
PfPKA-R the unbiased omit maps showed 
cAMP molecules clearly occupying each domainǯs nucleotide-binding site (Fig. 
4A,B).  Thus our structure represents the 
dissociated nucleotide-bound state of the 
regulatory subunit.   
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In CBD1 (Fig. 4B) a conserved 
phosphate binding cassette (PBC) pincers 
the cyclophosphate moiety of cAMP 
between the N-terminus of the ȽP helix 
and a conserved arginine (Arg-268), a 
position that also facilitates the formation 
of a H-bond between the cAMP hydroxyl 
group and Glu-259.  The residues making 
up these PBC-interactions are highly 
conserved across different CBD modules 
with equivalent residues present in CBD2 ȋȽPǯ, Arg-386ǯ and Glu-͵͹͹ǯ respectivelyȌ.  
The cyclic-nucleotides adenosine base 
projects outward where it is clamped on 
one side by hydrophobic residues 
originating from the Ⱦ4-Ⱦ5 loop (Ile-236 
and Leu-248 in CBD1 and Ile-͵͸͸ǯ in 
CBD2).  On the other side the base is 
clamped by a hydrophobic capping 
residue, the origin of which is an important 
point of distinction between the CBD1 and 
CBD2 binding sites: within CBD2 the 
cAMPǯ molecule is extensively buried by 
the subunitǯs C-terminal helix which 
overlays across it.  This ȽCǯ helix is 
positioned such that Tyr-ͶʹͶǯ forms a 
critical base-stacking interaction (Fig. 4A), 
which along with Val-Ͷʹ͹ǯ and Leu-Ͷʹͺǯ 
creates an enclosed hydrophobic cAMP-
binding site within this domain.  C-terminal to ȽCǯ a kink in the backbone 
structure brings Cys-Ͷ͵͹ǯ and )le-Ͷ͵ͺǯ 
back into proximity where they interact 
with cAMP near its N1-C2-N3 edge.  The 
CBD2 binding site is thus hydrophobic, 
masks the nucleotide from solvent and is 
entirely self-contained (the structure of 
PfPKA-R.297.441 is essentially CBD2 by 
itself in complex with cAMP, Fig. 4D). In 
contrast the CBD1 binding site is far more 
open and solvent exposed, Tyr-͵ͳͻǯ 
provides an analogous base-stacking 
hydrophobic cap (Fig. 4B) but importantly 
this residue actually originates from the N-
terminus of the CBD2 domainǯs ȽAǯ helix.  The ȽAǯ helix also contributes a second 
charged H-bond interaction between Asp-͵ͳ͹ǯ and the N͸ amide.  Direct allosteric 
inter-domain interactions are thus 
required to form the nucleotide-binding 
site of CBD1. 
 
Comparison with other known PKA 
regulatory subunits 
We compared the malarial PfPKA 
regulatory subunit structure with those of 
mammalian and yeast orthologues: that of 
B. taurus PKA type RIȽ (16) (25), R. 
norvegicus type RIIȾ (26) and S. cerevisiae 
Bcy1 (27).  Nucleotide-free holoenzyme 
structures of the mammalian orthologues 
are also known (17) (21) and were 
instrumental in elucidating the molecular 
basis of PKA signalling (Supp. Fig. 1).  
When RIȽ and RIIȾ are in complex with 
their shared kinase domain their 
structures align with their tandem CBDs 
lying separated on either end of their 
respective straight conjoined ȽB/C helices.  
This rigid helix, along with their ȽAǯ and ȽBǯ helices, forms a binding site for the 
large lobe of the catalytic domain (21) 
(Supp. Fig 1A).  cAMP-binding collapses 
this dumbbell shape, with the previously 
co-linear ȽB/C helix bending to reduce its 
length by up to 20% (Supp. Fig 1B).  This 
moves the CBD modules into contact with 
each other masking their ȽAǯ and ȽBǯ KD-
interacting surfaces, creating the active 
cAMP-bound form of their regulatory 
subunit, a form also reported for yeast 
Bcy1 (27).   While the two mammalian 
orthologues adopt similar structures in 
their kinase-associated state (17) (21) the 
CBD modules collapse together utilising 
different orientations upon cAMP binding. 
In RIȽ cAMP induces a bend in the 
previously rigid helix between ȽB and ȽC 
(Supp. Fig. 1B), while in RIIȾ the bend 
occurs midway along ȽC.  This distinction 
is important as it influences how their 
respective CBD2 modules rotate in the 
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cAMP-collapsed state.  In RIȽ the N-
terminus of ȽAǯ moves to become proximal 
to the cAMP base of CBD1 (17) (Fig. 5A), 
providing a hydrophobic-capping 
tryptophan that plays a role similar to that 
of Tyr-͵ͳͻǯ in PfPKA-R (Fig. 5B).  In 
contrast, the bending mechanism of RIIȾ 
moves the N-terminus of its ȽBǯ helix next 
to the adenine ring, capping it with an 
underlying arginine (21) in an orientation 
perpendicular to that of RIȽ (Fig. 5C).  Our 
cAMP-bound structure of PfPKA-R mimics 
RIȽ most closely (see Fig. 4C).  Plasmodium 
and RI regulatory subunits both interact 
with the adenine ring of cAMP via aromatic 
N-terminal ȽAǯ residues, whereas the RII 
isoforms utilise an ȽBǯ arginine (Fig. 5C).   
 
PfPKA-R also has R))Ⱦ-like features 
as each have long ȽCǯ helix that extensively 
bury their respective CBD2 nucleotide.  In 
PfPKA-R and R))Ⱦ the ȽCǯ helix is twice the 
length of that of RIȽ.  In PfPKA-R the first 
cAMP-binding site could thus be 
considered more similar to that of 
mammalian RI isoforms while the second 
site could be considered more reminiscent 
of RII (Fig. 5).  Both nucleotide-binding 
sites are important for signalling within 
the vertebrate PKA regulatory subunits 
(22).  In their holoenzyme state the CBD2 or ǲBǳ domain acts as a ǲgatekeeperǳ, lying 
exposed and ready for binding due to 
residues within the nucleotide-clamping ȽCǯ helix being disordered (21,28).  In 
PfPKA-R the ȽCǯ helix displays a degree of 
flexibility even in its cAMP-bound state, if 
we align the CBD2 domains from all 
protomers of our structures there are 
slight relative movements within ȽCǯ 
residues (Fig. 4D).  This appears to arise 
from slight deviations in backbone 
hydrogen-bond distances from those of an 
ideal Ƚ-helix for the clamping residue Tyr-
4ʹͶǯ. 
 
PfPKA-R shares ~39% sequence 
identity with mammalian type I and II 
isoforms but also displays a similar level of 
identity with the yeast regulatory subunit 
Bcy1 (27).  Despite sharing similar levels 
of sequence identity with Bcy1 and both 
being unicellular, PfPKA-R demonstrates 
closer structural homology to the 
mammalian regulatory subunits than that 
of yeast.  
 
The kinase domain interaction site 
Overall, the PfPKA-C subunit shares ~50% 
sequence identity with the mammalian 
catalytic subunits.  However, residues 
orthologous to those at the intersubunit 
docking interface of the mammalian 
holoenzymes are almost stringently 
conserved.  The cAMP-bound structures of 
RI and RII subunits are distinct, yet their 
holoenzyme forms overlay.  As the cAMP-
bound forms of PfPKA-R and mammalian 
RIȽ also overlay (R.M.S.D. of 2.7Å over 
227CȽ) it appears likely that the more 
stringently conserved holoenzyme 
docking interface will also closely 
resemble that of the mammalian isoforms.  
 )n mammalian PKAǯs an inhibitory 
pseudosubstrate region extends away 
from the CBDs and docks into the kinase 
domain (17) (21).  Upon cAMP-binding 
and dissociation these residues contract 
against CBD1 creating a ǲparkedǳ 
conformation stabilised via an arginine 
within the preceding linker interacting 
with negatively charged surface presented 
by ȽB, an interaction that facilitates PKA 
activation (29).   cAMP-bound PfPKA-R 
adopts an equivalent ǲparkedǳ 
intermolecular linker but the interactions 
stabilising its association with CBD1 are 
distinct; ȽB being primarily contacted by 
hydrophobic linker residues (Pro-167 and 
Val-169). 
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 The sequence of the PfPKA-R 
pseudosubstrate residues  
(145KKRLSVS151, see Fig. 3C) are most 
similar to the equivalent region of 
mammalian RI: they lack the flexible 
glycines of the RII sequence and Ser-149 
corresponds to the γ-phosphate-
interacting serine of RI.  Consistent with 
this assumption phosphorylation of Ser-
149 by PfPKA-C and Ser-151 by PfPKG is 
known to mitigate the inhibitory action of 
the PfPKA-R pseudosubstrate region (15).  
Although present in our construct, we 
were not able to observe what form these 
residues take perhaps indicating that they 
may be only partially ordered in the 
dissociated cAMP-bound state.  
 
Cyclic-AMP affinity measurements 
We developed the purification protocol 
described for apo-PfPKA-R.141.441 to 
eliminate scavenging of cyclic nucleotides 
from the bacterial lysate, representing a 
conformation of the subunit primed for 
binding to the catalytic subunit.  We next 
ascertained the binding kinetics of cAMP 
to this form of the PfPKA-R.  Protein 
sample at ~25μM within the cell of a 
Microcal isothermal titration calorimeter 
was titrated against sequential injections 
of cAMP (Fig. 6A).    
 
Approximate equilibrium 
thermodynamics for cAMP binding to 
PfPKA-R can be determined from the 
calorimetry data by fitting to the 
appropriate binding model.    cAMP 
binding resulted in an isotherm that was 
clearly uniphasic and was able to be fit 
with a single-site interaction model having 
ligand stoichiometry of 2.1±0.1.  If two 
binding-sites are known to be distinct a 
uniphasic isotherm typically results from 
positive cooperativity between the 
independent binding sites.  This can cause 
a tendency for the sites within each 
molecule to saturate together with a single 
enthalpic change of ΔH1+ΔH2 (30). In such 
circumstances fitting to a single-site 
interaction model is more robust and 
provides the binding constant for only the 
lowest affinity site; in our case yielding a 
Kd of ~1 nM (see Table 2) for the tandem 
CBDs of PfPKA-R.  Repeating the 
experiment for the CBD2 domain in 
isolation (Fig. 6B, Table 2) indicated the 
presence of only a single cAMP binding site 
with a nearly equivalent Kd of ~6 nM and 
is consistent with it being the binding site 
first occupied by cAMP.  
 
 
Inhibition of PfPKA-R blocks parasite 
proliferation. 
Differences between the cAMP binding 
sites of PfPKA-R and other eukaryotes 
raised the possibility that the subunit 
could be chemically exploited to 
dysregulate PKA signalling and arrest 
parasite proliferation.  To evaluate this P. 
falciparum chloroquine sensitive and 
resistant strains 3D7 and W2mef 
respectively, were grown in the presence 
of four membrane permeable, cyclic 
nucleotide phosphodiesterase (PDE) 
resistant cAMP analogues for 72 h. As a 
marker for parasite proliferation, the 
levels of lactate dehydrogenase activity 
were measured at different drug 
concentrations to calculate an EC50 for 
growth.  The most potent compound with 
an EC50 of 3.71 µM was Sp-2-Cl-cAMPS 
followed by Sp-8-Br-cAMPS with an EC50 
of 11.30 µM for 3D7 parasites (Fig. 7A).  
The cAMP analog 6-Bnz-cAMP was only 
weakly inhibitory at highest 
concentrations (Fig. 7A). The generic PKA-
C inhibitor H89 was included as a positive 
control as it had already been 
demonstrated to inhibit parasite growth 
(14) and with an EC50 5.76 µM was of 
similar potency as Sp-2-Cl-cAMPS (Fig 7A). 
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H89, Sp-2-Cl-cAMPS and Sp-8-Br-cAMPS 
blocked the proliferation of W2mef 
parasites nearly as well as 3D7 
demonstrating the compounds are 
effective against multiple parasite strains 
(data not shown).   
 
Sp-2-Cl-cAMPS relieves the allosteric 
inhibitory activity of Pf-PKA-R 
To provide evidence that the mechanism 
of action of the cAMP analogs was through 
dysregulation of PfPKA-R function we 
sought to determine if the analogs could 
reverse the inhibitory effects of 
supplementary apo-PfPKA-R in in vitro 
PKA-dependent phosphorylation assays.  
The phosphorylation assays were 
performed as in Fig. 2 with parasite lysate 
providing the kinase source, the tail of 
AMA1 being the protein substrate and a 
phospho S610 antibody being the 
detector.  The growth inhibitory Sp-2-Cl-
cAMPS and Sp-8-Br-cAMPS compounds 
were tested alongside a cAMP control and 
PfPKA dependent phosphorylation of the 
AMA1 substrate was reconstituted in their 
presence (Fig. 7B-D).  If the cAMP analogs 
act on PfPKA-R directly then they would be 
expected to alleviate the addition of 
supplementary apo-PfPKA-R.141.441.  
Following the addition of 0.5 or 1.5µM of 
PfPKA-R, high concentrations of Sp-2-Cl-
cAMPS and cAMP were effective at 
alleviating the subunitǯs allosteric 
inhibitory action with the analog being as 
effective as cAMP (Fig. 7B and D).  
Interestingly, the second analog Sp-8-Br-
cAMPS had difficulty overcoming apo-
PfPKA-R supplementation (Fig. 7C).  We 
repeated the isothermal titration 
calorimetry experiments with both 
analogs and found that Sp-2-Cl-cAMPS 
bound to the CBD2 domain of PfPKA-R 
with a Kd of ~9 nM (Fig. 6C, Table 2) 
equivalent to that of cAMP.  Moreover it 
bound effectively to both sites within the 
tandem CBD construct (Table 2).   In 
contrast Sp-8-Br-cAMPS had no detectable 
affinity for the CBD2 site of PfPKA-R (Fig. 
6D) and only bound the longer construct at 
a single site, presumably CBD1, with a Kd 
of 1.2μM. 
 
 
Sp-2-Cl-cAMPS binding to CBD2  
Finally we examined the mechanism of Sp-
2-Cl-cAMPS binding to the CBD2 domain of 
PfPKA-R.  Ligand-bound CBD2 crystals 
gave the best diffraction but still displayed 
significant anisotropy (2.4 Å on two axes 
and 3.8 Å resolution on the c axis). This 
was sufficient to allow a tentative model to 
be built and indicated Sp-2-Cl-cAMPS 
binding occurs in an almost identical 
manner as cAMP (Fig. 7E).  The 
thiophosphate modification is 
accommodated without obvious changes 
(Fig. 7E).  The additional chlorine on the adenosineǯs Cʹ carbon potentially requires 
a slight shift of the proteins extreme C-
terminal residues (Ͷ͵͹ǯ-441ǯ) to be 
accommodated (Fig. 7D,E); Our 1.1Å 
cAMP-bound structure would indicate a 
close contact if the C-terminus were to 
remain entirely stationary, but this 
movement is relatively minor.  The 
remaining interactions of the binding site 
including the base-stacking interaction 
with Tyr-ͶʹͶǯ appear largely unchanged.  Residues Ͷ͵͹ǯ-441ǯ are not directly 
associated with any crystal packing 
interface. 
 
If we overlay the structures of the 
other cAMP analogs tested onto our cAMP-
bound structures it indicates that unlike 
Sp-2-Cl-cAMPS they could not be 
accommodated without more serious 
structural changes.  The hydroxyl group of 
Tyr-͵͸ͻǯ makes a direct van der Waals 
contact with the C8 carbon and may be the 
cause for the reduced affinity for 8-
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Bromoadenosine analogues within CBD2. 
In contrast there is no obvious hindrance 
to Sp-8-Br-cAMPS binding within the 
PfPKA-R CBD1 site.  During the more 
extended growth assays this may be 
sufficient to effect a reasonable growth 
arrest (Fig. 7A) yet is insufficient to 
strongly alleviate the addition of 
recombinant PfPKA-R within the 
phosphorylation assay (Fig. 7C).  Our 
structures suggest Sp-2-Cl-cAMPS could 
be accommodated in both CBD sites.  
 )n vertebrate PKAǯs ͸-Bnz-cAMP is 
selective for the CBD1 or ǲAǳ site, yet our 
assays suggest it is ineffective at inducing 
growth arrest via interaction with PfPKA-
R (Fig. 7A).   It would clearly not be 
accommodated within CBD2 and a 
charged H-bond between Asp-͵ͳ͹ǯ and the 
N6-amide of cAMP may also limit its ability 
to interact within CBD1.   
 
Discussion 
 
The conserved cAMP-dependent 
protein kinases are a major regulator of 
signal transduction that arose prior to the 
origin of multi-cellularity in eukaryotes.  
Modern day unicellular eukaryotes often 
contain only a single catalytic/regulatory 
subunit pair but the increased 
requirement for signalling complexity in 
multicellular organisms such as 
vertebrates appears to have developed 
hand-in-hand with multi-component PKA 
signalling systems forged from gene 
duplications and subsequent isoform 
specialisation (32).  The structures of PKA 
regulatory subunits from vertebrates and 
S. cerevisiae have previously been 
compared (27) with the latter seen to have 
a novel fungal-specific quaternary 
structure and allosteric activation 
mechanism.  The structure of the P. 
falciparum PKA regulatory subunit 
represents the first from a human 
pathogen as well as that of a species 
evolutionary distant from previously 
studied vertebrate and yeast orthologues 
(16,17,21,25,26,33).   
 
In mammalian PKAs the two 
binding sites of the R subunits display 
positive cooperativity upon cAMP binding.  
The C-terminal CBDʹ, or ǲBǳ site, is always 
exposed and immediately available for 
nucleotide binding. When this site is 
occupied it stabilises structural changes 
within CBD1 that drastically increase its 
affinity for cAMP and promote subunit 
dissociation and hence activation (22).  
Our isothermal titration calorimetry data 
is consistent with PfPKA-R utilising a 
similar two-state cooperative binding 
mechanism that provides an enthalpically 
driven interaction with nanomolar affinity 
for cAMP, as in vertebrates (34).  Our 
structure of cAMP-bound PfPKA-
R.141.441 is consistent with this and 
details the interdomain interactions 
between the CBD modules. 
 
The compact cAMP-bound 
conformation of PfPKA-R has features 
reminiscent of both mammalian 
regulatory subtypes.  The allosteric 
interface that creates the CBD1 nucleotide-
binding site resembles that of RI (27).  This 
may be indicative of it being the more 
ancestral allosteric regulatory 
architecture, with the orthogonal CBD 
interaction of RII isoforms and that of Bcy1 
perhaps later evolutionary developments.  
Meanwhile the self-contained CBD2 
binding site of PfPKA-R extensively buries 
its adenosine base using a large 
hydrophobic C-terminal helix in a manner 
similar to that of the RII isoforms yielding 
a hybrid set of vertebrate features.  The 
differences between the cAMP-binding 
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sites of RI and RII have led others to 
identify compounds that selectively 
activate the different mammalian 
isoforms; cAMP analogues containing N6-
substitutions preferentially bind RII while 
C8-substitutions target type RI (35).  The 
CBD1 domain of PfPKA-R is relatively open 
within the plane of the base and 
accordingly may accommodate a number 
of adenosine-modified cAMP analogs. In 
contrast the adenosine base within the 
CBD2 domain is extensively buried in our 
structures with C2 modified bases 
appearing to be most easily 
accommodated. 
 
We then showed that some 
membrane-permeable cAMP analogues 
disrupt P. falciparum growth; thus while 
PKA activity is necessary for parasite 
growth the timing of that activity is also 
critical.  It would be appealing to identify 
ligands that more selectively target PfPKA-
R than those of their human host.  Our Sp-
2-Cl-cAMPS bound structure highlights 
one of the unique features of the CBD2 
cAMP-binding site in Plasmodium sp.; the 
proximity of Cys-Ͷ͵͹ǯ and its interactions 
near C2 of the adenosine base.  Due to the 
conservation of Cys-Ͷ͵͹ǯ amongst 
Plasmodium species it may stand as a 
useful point-of-difference that could be 
productively targeted when attempting to 
create Plasmodium-specific PKA 
activators.  The action of Sp-2-Cl-cAMPS on 
PKA phosphorylation demonstrates that 
C2 modifications near Cys-Ͷ͵͹ǯ are well 
tolerated and disrupt erythrocytic stage 
parasite growth at low micromolar 
concentrations. 
 
 Erythrocytic stage P. falciparum 
growth was effectively inhibited by Sp-2-
Cl-cAMPS, however the therapeutic 
potential of this compound is reduced by 
its potential to influence human R 
isoforms.  Given the low similarity of 
PfPKA-R to orthologous human proteins 
more specific allosteric agonists could, in 
theory, be developed. Our current work 
focuses on direct interference of cAMP 
sensing, yet the phosphate binding 
cassettes are a highly conserved part of the 
fold.  Greater specificity may be obtained 
by targeting compounds to other sites 
within PfPKA-R such as near the inter-CBD 
interface or the intermolecular linker N-
terminal to CBD1.  Moreover the function 
of the PfPKA-R N-terminus and its 
essentiality to the parasite remain to be 
ascertained. 
 
Despite their divergent 
evolutionary history, the regulatory 
architecture of PKA signalling in 
Plasmodium parasites and their hosts 
bears recognisable similarities.  We 
provide a first glimpse at the molecular 
details of cAMP signalling in a major 
human pathogen and detail the residues 
involved in providing allosteric 
cooperativity between its two CBD 
domains.  Moreover while compounds 
blocking the kinase activity of PfPKA-C are 
known to limit parasite growth (14), we 
herein demonstrate that uncontrolled 
premature activation of PfPKA-R is equally 
disruptive to parasite survival. 
 
 
 
MATERIALS AND METHODS 
 
Protein cloning and expression -
Synthetic cDNA encoding the Plasmodium 
falciparum 3D7 PKA regulator subunit 
(PF3D7_1436600) was cloned into pET-
28b based expression vector.  Five 
different constructs were made consisting 
of PKAR residues 1-441, 69-441, 141-441, 
297-441 and 141-297.  Recombinant 
protein was expressed in E. coli 
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BL21(DE3) cells grown for 4 hours at 37°C 
in Luria Broth containing 34 μM 
kanamycin before being induced for 4 
hours with 0.1 mM Isopropyl 
thiogalactopyranoside.   Cells were 
harvested and resuspended in buffer A (20 
mM HEPES pH 7.5, 250 mM NaCl, 1 mM 
TCEP) with 20 mM imidazole prior to lysis 
with 1 mg/mL lysozyme and DNAase along 
with 5 min sonication on ice; cell lysate 
was clarified by centrifugation and loaded 
onto immobilised metal affinity column 
with the bound material then washed 
extensively with Buffer A before being 
eluted in Buffer supplemented with 400 
mM Imidazole. After elution from the 
IMAC column the hexahistidine tag was 
removed by incubating at 4°C overnight 
with 0.5 mg human rhinovirus-3c 
protease.  After exchanging into 20 mM 
HEPES pH 7.5, 50 mM NaCl, 1 mM TCEP 
PfPKA-R was loaded onto a 1 mL HiTrap-
SP cation exchange column and eluted 
under a 25 mL gradient to buffer A with 
1M NaCl.  Protein eluted as a single peak 
and was subsequently loaded onto size 
exclusion chromatography column 
equilibrated with Buffer A. 
 
When apo PfPKA-R was required 
the protein was purified as per normal but 
after loading onto the IMAC column bound 
material was washed extensively with 20 
mM HEPES pH 7.5, 8M urea, 250mM NaCl, 
1mM TCEP before slowly exchanging back 
into buffer A. 
 
Culture of Plasmodium falciparum - P. 
falciparum asexual stage parasites were 
cultured in human erythrocytes (blood 
group O+) supplied by the Australian Red 
Cross Blood Bank at 4% haematocrit in 
RPMI-HEPES medium supplemented with 
0.43% AlbumaxII Lipid Rich Bovine Serum 
(GIBCO) and 0.18% NaHCO3 as previously 
described (36). Lysates for 
phosphorylation were made from late 
stage schizonts 42-46 hours post invasion 
at 2% parasitemia. The schizonts were 
treated with 0.09% saponin in PBS and 
Roche Complete protease inhibitors to lyse 
the membranes of their erythrocytes.  The 
erythrocyte contents including 
hemoglobin and human PKA were 
removed by washing the parasite cells 
multiple times in PBS and frozen at -80°C.  
Immediately prior to performing 
phosphorylation reactions the parasite 
pellets were thawed in 20mM Tris pH 
7.4, 1% Triton, 150mM NaCl, 20mM MgCl2, 
1mM ATP, 1mM DTT with Roche 
PhosSTOP phosphatase inhibitors and 
Roche Complete protease inhibitors.  
Before use the lysates were cleared by 
centrifugation and a volume equivalent to 
0.2 µL of pelleted saponin lysed schizonts 
was used per reaction (see below).  
 
Functional validation of recombinant 
PfPKA-R - Nunc MaxiSorp 96 well ELISA plates were coated with ͳμg/ml of GST-
PfAMA1 (8) substrate overnight at Ͷ˚C. 
Coated plates were subsequently blocked 
in 1% bovine serum albumin (BSA) in tris-
buffered saline (TBS) for 1 h prior to 
initiation of phosphorylation reactions in 
kinase activity buffer (20 mM Tris, 20 mM 
MgCl2, 2 mM MnCl2, 1 mM DTT, Roche 
PhosSTOP) supplemented with lysates 
made from P. falciparum late stage 
schizonts and ͳͲͲμM ATP and Ͳ-ͺμM 
cAMP. Recombinant PfPKA-R (5, 1.5, 0.5 or 
0 µM) was titrated in to the 
phosphorylation reactions in either an 
active or heat-inactivated state ȋ͹Ͳ˚C/ͳͷ 
mins prior to placement on ice/10 mins) at ͵͹˚C/30 mins. Following the reaction the 
wells were washed three times with TBS 
and probed with rabbit anti-phospho- 
PfAMA1S610 antibodies raised to the 
synthetic peptide SFWGEEKRASpHTTPV 
phosphorylated on the S610 residue 
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(Genscript). The resulting antisera had 
been depleted of non-phospho-specific 
antibodies by depletion against a non-
phosphorylated version of the peptide 
(Genscript).  The ELISA plates were 
washed as before and subsequently 
probed with goat anti-rabbit-HRP 
(Abcam) at room temperature/shaking. 
Following washing, 2,2′-Azino-bis(3-
ethylbenzothiazoline-6-sulfonic acid) was 
added (30 min/shaking) to develop the 
assay and the reaction was stopped by 
addition of 1% SDS before reading at 
405nm on a spectrophotometer. 
Absorbance values were plotted in Prism 6 
(GraphPad). 
 
Parasite proliferation assays - Asexual 
blood stage P. falciparum parasites were 
cultured for 72 h in a dilution series of 
cAMP analogs Sp-8-Br-cAMPS (8- 
bromoadenosine- 3', 5'- cyclic 
monophosphorothioate, Sp-isomer 
[CalBiochem]), 6-Bnz-cAMP (N6- 
benzoyladenosine- 3', 5'- cyclic 
monophosphate [BioLog]) and Sp-2-Cl-
cAMPS (2- chloroadenosine- 3', 5'- cyclic 
monophosphorothioate, Sp-isomer 
[BioLog]). H-89 dihydrochloride hydrate 
was from Sigma. After culturing lactate 
dehydrogenase activity was measured 
using a modified form of the Malstat assay 
(23,37).  
 
 
Protein crystallisation - PfPKA-R.141.441 
at 12 mg/mL with 2mM cAMP was 
crystallised at 4°C within a hanging drop 
vapour diffusion experiment.   Protein 
drops were set in a 1:1 ratio against a 
reservoir consisting of 20% w/v 
Polyethylene glycol 3350, 0.1M NaF and 
0.1M 1,3-bispropane pH 7.5, with crystals 
appearing after 7-10 days.  Crystals were 
transferred into a cryoprotectant 
consisting of reservoir and 250 mg/mL 
sucrose before being plunged into liquid 
nitrogen. 
 
PfPKA-R.297.441 at 4 mg/mL with 
2mM cAMP also crystallised at 4°C in a 
similar experiment using a reservoir 
consisting of 22% w/v polyethylene glycol 
6000, 0.1M LiCl and 0.1M CH3COONa pH 4.  
Apo-PfPKA-R.297.441 without removal of 
the his-tag at 6 mg/mL with 2mM Sp-2-Cl-
cAMPS was crystallised at 22°C over a 
reservoir consisting of 20% w/v 
polyethylene glycol 3350, 0.2M NH4I.  
Prior to being plunged into liquid nitrogen 
crystals were transferred into a solution 
containing 250 mg/mL sucrose as 
cryoprotectant. 
 
Data collection and structure solution - 
X-ray diffraction data was collected at the 
Australian synchrotron MX1 and MX2 
beamlines.   Data was integrated and 
scaled with the programs imosflm and 
Scala.  A trimmed version of the bovine 
PKA-R subunit (16) was used as a 
molecular replacement probe in the 
program Phaser (38).  The resulting model 
was then improved by simulated 
annealing and rounds of manual building 
and refinement using the programs COOT 
(39)  and PHENIX (40).  The final PfPKA-
R.297.441 model has two protomers in the 
ASU, with all residues observed along with 
two molecules of cAMP.  The final PfPKA-
R.141.441 model consists of two 
molecules within the asymmetric unit with 
clear electron density for residues 167-
441, 4 molecules of cAMP and 4 tentatively 
identified N-terminal residues.   
 
Isothermal titration calorimetry - Apo 
PfPKA-R.141.441 or PfPKA-R.297.441 
were purified, concentrated and finally 
dialyzed overnight against buffer 
containing 20 mM HEPES, pH 7.0, 150 mM 
NaCl, 0.5mM TCEP.  After dialysis the 
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protein concentration was adjusted to 
~0.026 mM.  Cyclic nucleotides used for 
titration were prepared using the dialysis 
buffer to a final concentration of 0.5 mM.   
ITC measurements were performed with a 
MicroCal VP-ITC calorimeter (GE 
Healthcare) at 25°C. Nucleotides were 
injected 50-70 times (1 μL for the first two 
injections and 2 μL for subsequent 
injections), with 240 s intervals between 
injections.  Background data obtained 
from the buffer sample were subtracted 
before data analysis. All data were fitted 
using the Origin 7.0 software package 
(MicroCal, Northampton, MA). Two 
independent measurements were 
performed with errors representing the 
standard deviation of fitted constants.  
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Table 1 - Data collection and refinement statistics 
 PKAR.141.441 PKAR.297.441 PKAR.297.441 
Data collection  cAMP bound cAMP bound Sp-2Cl-cAMPS bound 
Space group P21212 P212121 P43212 
Wavelength 
 
0.9537 0.9537 0.9537 
    a, b, c (Å) 78.7, 103.8, 104.2 39.3, 71.8, 106.5 64.2, 64.2, 195.7 
Resolution (Å) 46.6-2.00 (2.11-2.00) 42.8-1.15 (1.21-1.15) 37.3-2.40 (2.53-2.40) 
Rpim1 3.1 (55.5) 4.1 (44.0) 3.8 (31.6) 
I/1 12.4 (1.6) 9.7 (1.8) 11.2 (2.2) 
Completeness (%) 100.0 (100.0) 97.2 (89.5) 99.9 (100.0) 
No.  unique observations 58452 (8419) 104403 (13799) 16863 (2389) 
Multiplicity 9.0 (9.1) 7.9  (5.9) 11.2  (11.6) 
    
Refinement statistics    
Rfactor 2 (%) 24.5 (36.0) 19.8 (29.0) 25.1 (32.3) 
Rfree 3 (%) 28.5 (37.8) 21.8 (33.2) 30.7 (38.1) 
No. atoms 
   Protein 
   Water (cAMP) 
 
4534 
36 (4) 
 
2469 
356 (2) 
 
2392 
10 (2 cAMPS; 5I-) 
Ramachandran plot (%)   Most favoured  Allowed region   
Outlier 
 
97.1 
2.9 
0.0 
 
98.7 
1.2 
0.0 
 
96.1 
3.9 
0.0 
B-factors (Å2)     Protein   66.1  22.0  93.3 
rmsd bonds (Å) 0.009 0.012 0.014 
rmsd angles () 1.26 1.31 2.2 
PDB 5KBF 5K8S 5T3N 
     
 
1
 Rp.i.m = hkl [1/(N-1)]1/2  i | Ihkl, i - <Ihkl> | / hkl <Ihkl> 
2
 Rfactor = (  | |Fo| - |Fc| | ) / (  |Fo| )  - for all data except as indicated in footnote 3. 
3
 5% of data was used for the Rfree calculation  
Values in parentheses refer to the highest resolution bin 
 
 
Table 2 - Isothermal calorimetry binding constants 
Construct Ligand N 
Kd 
(nM)1 
ΔH 
(kcal mol-1) 
ΔS 
(cal mol-1 K-
1) 
PfPKAR.141.441 cAMP 2.1±0.1 1.2  ± 0.2 -18.9 ± 0.6 -22 ± 2 
PfPKAR.141.441 Sp-8-Br-cAMPS 1.2 ± 0.1 
1300 ± 
850 
-10.5 ± 2 -8.1 ± 1.1 
PfPKAR.141.441 Sp-2-Cl-cAMPS 2.1 ± 0.1 8.9 ± 4 -11.9 ± 0.4 -3 ± 2 
PfPKAR.297.441 cAMP 0.9 ± 0.1 6.0 ± 0.6 -11.1 ± 0.1 -0.2 ± 0.3 
PfPKAR.297.441 Sp-8-Br-cAMPS - N.D. N.D. N.D. 
PfPKAR.297.441 Sp-2-Cl-cAMPS 0.9 ± 0.1 9.1 ± 11 -7.1 ± 0.1 11.7 ± 0.9 
1 Determined at 295K  
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Figure 1. Domain structure of Plasmodium PKA regulatory subunit. 
Diagram of Plasmodium falciparum PKA regulatory (PfPKA-R) gene showing regions expressed for functional 
and structural analysis. (Left) PfPKA-R has two cAMP binding regions CBD1 and CBD2, inhibitory sequence 
(IS) and predicted N-myristoylation (Gly-2) and palmitoylation (Cys-5) sites for membrane anchorage. Four 
regions of PfPKA-R were expressed of which two generated high yield (right, 141-441/297-441). 
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Figure 2. Recombinant apo-PfPKA-R inhibits PKA-mediated phosphorylation 
 (A) Illustration of the ELISA based phosphorylation assay using the recombinant tail of AMA1, a validated 
PfPKA target. (B) Native phosphorylation activity of PfPKA-C (indicated by OD 405 nm), can be efficiently 
inhibited by addition of recombinant apo-PfPKA-R in a concentration-dependent manner. This effect can be 
efficiently reversed by addition of supplementary cAMP and is due specifically to the apo-PfPKA-R as the 
inhibitory effect of the fragment is lost upon heat denaturation (heat inactivated). Each data point and 
whiskers are the mean/standard deviation of two technical replicates. Graph shown is representative of three 
independent biological replicates.  
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Figure 3 Structure of PfPKA-R 
A) Schematic representation of the mammalian PKA holoenzyme and its activation mechanism. Catalytic 
domain depicted in gray, CBD1 and CBD2 domains in blue and purple.  B) Cartoon representation of the 
nucleotide bound PfPKA-R structure. Ⱦ-strands are coloured tan, CBDͳ Ƚ-helices blue and CBDʹ Ƚ-helices 
purple.  All secondary structure elements are labelled within each CBD.  The two bound cAMP molecules are 
shown in red. C) Sequence alignment of the residues within the respective CBD domains for the PKA-R 
subunits from P. falciparum, P. vinckei vinckei, T. gondii, and H. sapiens R)Ƚ and R))Ⱦ.  The conserved PBC 
arginines are highlighted in black, the ȽP glutamates and the tyrosine with which they interact in red, and the 
inhibitory sequence in pink.   
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Figure 4  Structure of the cAMP binding sites within PfPKA-R. 
A) Residues within the cyclic-AMP binding site of CBD2 as observed within the 1.1Å PfPKAR.297.441 
structure.  The nucleotide is clearly bound as seen in the Fo-Fc omit map contoured at 3.4σ.  The main residues 
contributing to the binding site are displayed in stick representation.  B) The CBD1 cAMP-binding site as 
observed within the 2.0Å PfPKAR.141.441 structure. Tyr-319 is highlighted.  C) Backbone alignment of 
PfPKA-R with the orthologous cAMP-bound structure of B. tarus PKA-R (in green). The bound nucleotides of 
BtPKA-R are coloured light brown while PfPKA-R is depicted using the colour scheme of Fig. 2B.  D) Potential 
mobility of the helical elements of the CBD2 domain can be seen when comparing an alignment of its 
structure ascertained from the different crystals. 
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Figure 5 - Comparison of the cAMP-binding domains in the known structures of PKA orthologues. 
A) Cartoon representation of the A- or CBD1 cAMP-binding site from Bos taurus type RIȽ (25). Helices within 
CBD1 are coloured aquamarine and those within CBD2 teal, the bound cAMP is shown in red.  The 
interdomain interfacial hydrophobic capping tryptophan contributed by ȽAǯ is shown in stick representation.  
Similar representations are presented for the CBD1 domains of B) PfPKA-R and C) RnPKA-R IIb (26).  Similar 
representations of the CBD2 domains are presented for D) BtPKA-RIȽ. E) PfPKA-R and F) RnPKA-RIIȾ.  Yellow 
arrows indicate the orthologue structures each malarial PfPKA-R binding domain is most similar to. 
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Figure 6 – Isothermal titration calorimetry affinity measurements 
A) Binding isotherm measured at 295K for the interaction between cAMP and apo-PfPKA-R.141.441, below is 
the resulting thermogram obtained from the integrated heats using a one-site binding model.  Equivalent 
experiments for binding to the CBD2 site of apo-PfPKA-R.297.441 are shown for B) cAMP, C) Sp-2-Cl-cAMPS 
and D) Sp-8-Br-cAMPS. 
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Figure 7. Compounds binding PfPKA-R block parasite proliferation and causes PKA 
dysregulation. (A) Four cAMP analogs and the PKA-C inhibitor H89 were assessed for their capacity to block 
proliferation of the asexual blood stage of P. falciparum 3D7 parasite strain. After 72 h of growth in serial 
dilutions of the compounds the levels of the parasite enzyme lactate dehydrogenase were measured at OD650 
nm and growth curves are presented.  Mean EC50s and SEMs for three replicates are shown on the right.  (B-D)  
Cyclic AMP and its analogs can stimulate PKA phosphorylation.  The level of phosphorylation of an immobilised 
AMA1 substrate was detected using an anti-phospho-AMA1 S610 protein and measured using an anti-rabbit 
HRP conjugate producing a colormetric change quantified at 405 nm.  Parasite lysate provided the source of 
PKA-C whose activity was stimulated with the compounds indicated. Supplementary recombinant apo-PfPKA-
R was added to verify if this protein was the target of the cAMP analogs whose structures are shown. Each data 
point and whiskers are the mean and standard deviations of duplicate measurements. Representative graphs 
of three independent experiments are shown.  (E) The structure of Sp-2-Cl-cAMPS bound PfPKA-R.297.441 is 
shown, residues capable of forming van der Waals interactions with the ʹǯ-Cl are highlighted with black lines.  
Colouring and labelling are as used in Fig. 4A, the Fo-Fc omit map generated during refinement contoured at 3σ 
is displayed with a green surface representation.  For clarity the 1st half of Cǯ is not displayed.   
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